Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
Rhea-AI Summary
Neurocrine Biosciences (NASDAQ: NBIX) will release its third quarter 2025 financial results and host a conference call and webcast on October 28, 2025. The press release is scheduled for 1:00 p.m. PT / 4:00 p.m. ET, followed by the conference call at 1:30 p.m. PT / 4:30 p.m. ET.
Dial-in numbers: Domestic 800-274-8461, International 203-518-9814 with Conference ID: NBIX. The webcast will be available on the company's Investors page at neurocrine.com, with a replay posted about one hour after the event and archived for ~one month.
Positive
- None.
Negative
- None.
News Market Reaction – NBIX
In the Oct 8 session, NBIX gained 1.52%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Tuesday, October 28
The schedule for the press release and conference call / webcast is as follows:
- Q3 2025 Press Release: October 28, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
- Q3 2025 Conference Call: October 28, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-274-8461
- International Dial-In Number: 203-518-9814
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2025-financial-results-302577461.html
SOURCE Neurocrine Biosciences, Inc.